PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

192 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... 7 ... 8 ... 9 ... 10 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
1.
Damaskou, A.* et al.: Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML. Blood, DOI: 10.1182/blood.2024026113 (2025)
2.
Gottschlich, A.* et al.: Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood 145, 1536-1552 (2025)
3.
Pelzl, R.* et al.: Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment. Blood, DOI: 10.1182/blood.2024027877 (2025)
4.
Kobold, S.: Giving T-cell bispecifics a helping hand. Blood 143, 2115-2116 (2024)
5.
Bamezai, S.* et al.: A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood 142, 90-105 (2023)
6.
Barbosa, K.O.* et al.: Transcriptional control of leukemogenesis by the chromatin reader SGF29. Blood 143, 697-712 (2023)
7.
Frenz-Wiessner, S.* et al.: Human Induced Pluripotent Stem Cell-Derived Bone Marrow Organoids to Model Hematopoietic Development. Blood 142:2708 (2023)
8.
Ghalandary et al.: WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice. Blood 141, 955-960 (2023)
9.
Linder, M.I.* et al.: Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes. Blood 141, 645-658 (2023)
10.
Roas, M.* et al.: Targeting FLT3 by new-generation antibody-drug-conjugate in combination with kinase inhibitors for treatment of AML. Blood 141, 1023-1035 (2023)
11.
Schuetz, C.* et al.: Hypomorphic RAG deficiency: Impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT. Blood 141, 713-724 (2023)
12.
Wimberger, N. et al.: Oncogene-induced MALT1 protease activity drives post-transcriptional gene expression in malignant lymphomas. Blood 142, 1985-2001 (2023)
13.
Janssen, M.* et al.: Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood 140, 2594–2610 (2022)
14.
Philipp, N.* et al.: T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140, 1104-1118 (2022)
15.
Augsberger, C.* et al.: Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody. Blood 138, 2655-2669 (2021)
16.
Chen, B.R.* et al.: A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis In AF10-rearranged AML. Blood 137, 3403-3415 (2021)
17.
Chen, J.* et al.: ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia. Blood 137, 3629-3640 (2021)
18.
Deng, Y.* et al.: CD27 is required for protective lytic EBV antigen specific CD8+ T cell expansion. Blood 137, 3225-3236 (2021)
19.
Frey, L.* et al.: Mammalian VPS45 orchestrates trafficking through the endosomal system. Blood 137, 1932-1944 (2021)
20.
Hecker, J.S.* et al.: CHIP & HIPs: Clonal hematopoiesis is common in hip arthroplasty patients and associates with autoimmune disease. Blood 138, 1727-1732 (2021)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... 7 ... 8 ... 9 ... 10 ... ▶▶ ▶▮